Atopic dermatitis differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Line 15: | Line 15: | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquired | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquired | ||
! colspan="13" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ! colspan="13" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ||
! colspan=" | ! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ||
Line 24: | Line 24: | ||
! colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ! colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ||
|- | |- | ||
! colspan=" | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
|- | |- | ||
Line 38: | Line 37: | ||
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Single/ | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Single/ | ||
Line 93: | Line 89: | ||
(Eosinophilia) | (Eosinophilia) | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 139: | Line 131: | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |NA | | align="center" style="background:#F5F5F5;" |NA | ||
| align="center" style="background:#F5F5F5;" | Clinical manifestation + [[Patch test (medicine)|patch test]] | | align="center" style="background:#F5F5F5;" | Clinical manifestation + [[Patch test (medicine)|patch test]] | ||
Line 173: | Line 161: | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Spongiosis | * Spongiosis | ||
Line 200: | Line 184: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 250: | Line 230: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 287: | Line 263: | ||
* Color of plaque varies fro, yellow to reddish brown | * Color of plaque varies fro, yellow to reddish brown | ||
* Plaque size can vary between 3X6 cm 6X10 cm areas. | * Plaque size can vary between 3X6 cm 6X10 cm areas. | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 334: | Line 306: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Scales can vary from mild scaling to large, plate (armor)-like scales and thickening of the skin. | * Scales can vary from mild scaling to large, plate (armor)-like scales and thickening of the skin. | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 377: | Line 345: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Chronically lesions result into central clearing leading to annular lesions. | * Chronically lesions result into central clearing leading to annular lesions. | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 429: | Line 393: | ||
* ↑ serum immunoglobulin E (IgE) levels | * ↑ serum immunoglobulin E (IgE) levels | ||
* ↑ Eosinophilia | * ↑ Eosinophilia | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 468: | Line 428: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
Line 478: | Line 434: | ||
! rowspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection | ! rowspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Dermatophyte|Dermatophytes]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Dermatophyte|Dermatophytes]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 506: | Line 458: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Candidiasis|Candida]] | ! align="center" style="background:#DCDCDC;" |[[Candidiasis|Candida]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 534: | Line 482: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Herpes simplex]] | ! align="center" style="background:#DCDCDC;" |[[Herpes simplex]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 562: | Line 506: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Staphylococcus aureus]] | ! align="center" style="background:#DCDCDC;" |[[Staphylococcus aureus]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 613: | Line 553: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | If molluscum contagiosum is acquired as sexually transmitted disease, it involves, groin and genital region. | | align="center" style="background:#F5F5F5;" | If molluscum contagiosum is acquired as sexually transmitted disease, it involves, groin and genital region. | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 640: | Line 576: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | +++ | | align="center" style="background:#F5F5F5;" | +++ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 658: | Line 590: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Human Immunodeficiency Virus (HIV)|HIV]] | ! align="center" style="background:#DCDCDC;" |[[Human Immunodeficiency Virus (HIV)|HIV]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 706: | Line 634: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
Line 739: | Line 663: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Oral manifestation such as vesicles and erosion may be present | * Oral manifestation such as vesicles and erosion may be present | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 789: | Line 709: | ||
* ↑ Eosinophilia | * ↑ Eosinophilia | ||
| align="center" style="background:#F5F5F5;" | Thrombocytopenia | | align="center" style="background:#F5F5F5;" | Thrombocytopenia | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 848: | Line 764: | ||
* ↑ Eosinophilia | * ↑ Eosinophilia | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 860: | Line 772: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[22q11.2 deletion syndrome|DiGeorge syndrome]] | ! align="center" style="background:#DCDCDC;" |[[22q11.2 deletion syndrome|DiGeorge syndrome]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 888: | Line 796: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Severe combined immunodeficiency]] ([[Severe combined immunodeficiency|SCID]]) | ! align="center" style="background:#DCDCDC;" |[[Severe combined immunodeficiency]] ([[Severe combined immunodeficiency|SCID]]) | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 916: | Line 820: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Ataxia telangiectasia]] | ! align="center" style="background:#DCDCDC;" |[[Ataxia telangiectasia]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 964: | Line 864: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
Line 974: | Line 870: | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Metabolic Diseases | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Metabolic Diseases | ||
! align="center" style="background:#DCDCDC;" |[[Phenylketonuria]] | ! align="center" style="background:#DCDCDC;" |[[Phenylketonuria]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,002: | Line 894: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Tyrosinemia]] | ! align="center" style="background:#DCDCDC;" |[[Tyrosinemia]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,030: | Line 918: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Histidinemia]] | ! align="center" style="background:#DCDCDC;" |[[Histidinemia]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,058: | Line 942: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Multiple carboxylase deficiency]] | ! align="center" style="background:#DCDCDC;" |[[Multiple carboxylase deficiency]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,087: | Line 967: | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nutritional deficiencies | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nutritional deficiencies | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Zinc deficiency]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Zinc deficiency]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,115: | Line 991: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Pellagra|Niacin (B3) deficiency]] | ! align="center" style="background:#DCDCDC;" |[[Pellagra|Niacin (B3) deficiency]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,143: | Line 1,015: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Pyridoxine deficiency|Pyridoxine (B6) deficiency]] | ! align="center" style="background:#DCDCDC;" |[[Pyridoxine deficiency|Pyridoxine (B6) deficiency]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,171: | Line 1,039: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Biotin deficiency|Biotin (B7) deficiency]] | ! align="center" style="background:#DCDCDC;" |[[Biotin deficiency|Biotin (B7) deficiency]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,200: | Line 1,064: | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cutaneous T cell lymphoma|Mycosis fungoides]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cutaneous T cell lymphoma|Mycosis fungoides]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,228: | Line 1,088: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Langerhans cell histiocytosis|Histiocytosis X]] | ! align="center" style="background:#DCDCDC;" |[[Langerhans cell histiocytosis|Histiocytosis X]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,257: | Line 1,113: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Medications | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Medications | ||
! align="center" style="background:#DCDCDC;" |[[Infliximab]] | ! align="center" style="background:#DCDCDC;" |[[Infliximab]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,306: | Line 1,158: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard |
Revision as of 21:30, 24 October 2018
Atopic dermatitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Atopic dermatitis differential diagnosis On the Web |
American Roentgen Ray Society Images of Atopic dermatitis differential diagnosis |
Risk calculators and risk factors forAtopic dermatitis differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Differentiating Atopic Dermatitis from other Diseases
Category | Diseases | Etiology | Inherited | Acquired | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Demography | History and risk factors | Symptoms | Physical examination | ||||||||||||||||||||
Lab Findings | Histopathology | ||||||||||||||||||||||
Appearance | Itching | Bleeding | Fever | BP | Tenderness | Nail pitting | Other | CBC | ESR/CRP | ||||||||||||||
Single/
Multiple |
Rash | Involved areas | Pustule | WBC | Platelets | ||||||||||||||||||
Skin disorders | Atopic dermatitis |
|
+ | + |
|
|
Multiple |
|
– | + | – | – | NA | – | – |
|
Nl to ↑
(Eosinophilia) |
Nl | Nl |
|
Clinical manifestation |
| |
Allergic contact dermatitis[1] |
|
– | + | Any |
|
May be multiple after 1-2 days of exposure | Erythematous well-demarcated papules | Surrounding the area in contact with the offending agent | – | + | – | – | Nl | + | – |
|
Nl to ↑
(Eosinophilia) |
Nl | Nl | NA | Clinical manifestation + patch test |
| |
Irritant contact dermatitis[2] |
|
– | + | Any, more occupational exposure |
|
Usually single immediately after the exposure | Well-demarcated red patch with a glazed surface | Any area in contact with the irritant | – | + | – | – | Nl | + | – |
|
Nl | Nl | Nl |
|
Clinical manifestation + patch test |
| |
Seborrheic dermatitis |
|
– | + | Any, onset during the 1st days or weeks of life |
|
Greasy scaling on a yellow-red base | Scalp, axilla, and diaper area | – | |||||||||||||||
Psoriasis |
|
+ | + | Any, 2 peaks of onset 30-39 years and 50-59 years |
|
Multiple | Well-circumscribed, pink papules and symmetrically distributed cutaneous plaques with silvery scales |
|
+ | + | +
Auspitz sign (pinpoint bleeding) |
_ | Nl | + | + | ||||||||
Lichen simplex [3]chronicus |
|
– | + | Any, peak at 30-50 years of age |
|
Multiple | Lichenified and erythematous, pruritic exudative plaque, and excoriations | Scalp, head, neck, hands, arms, and genitals areas | – | + | – | – | Nl | – | – |
|
Nl | Nl | Nl |
|
Clinical manifestation |
| |
Ichthyosis vulgaris[4] |
|
+ | + | Usually in infancy |
|
Multiple |
|
|
– | – | – | – | Nl | – | – |
|
Nl | Nl | Nl |
|
Clinical manifestation |
| |
Nummular dermatitis (discoid eczema) | Unknown | – | + | Any, two peaks, 6th-7th decade of life in males and 2nd-3rd decade of life in females |
|
Multiple | Nl |
|
– | + | – | – | Nl | – | – |
|
Nl | Nl | Nl |
|
Clinical manifestation |
| |
Netherton's syndrome[5] | Autosomal recessive mutations in the serine protease inhibitor of Kazal type 5 gene (SPINK5), encoding LEKTI, a serine protease inhibitor | + | – | Affects neonates |
|
Multiple |
|
|
+ | + | – | – | Nl | – | – |
|
|
Nl | Nl |
|
Clinical manifestation |
| |
Diseases | Etiology | Inherited | Acquired | Demography | History and risk factors | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | BP | Tenderness | Nail pitting | Other | WBC | Platelets | ESR/CRP | Histopathology | Gold standard | Additional findings | |
Infection | Dermatophytes | ||||||||||||||||||||||
Candida | |||||||||||||||||||||||
Herpes simplex | |||||||||||||||||||||||
Staphylococcus aureus | |||||||||||||||||||||||
Molluscum contagiosum | Molluscum contagiosum virus inoculation through direct skin contact | – | + | Any, peak among children >5 years of age and young adults |
|
Multiple |
|
|
– | + | – | – | Nl | – | – | If molluscum contagiosum is acquired as sexually transmitted disease, it involves, groin and genital region. | Nl | Nl | Nl |
|
Clinical manifestation | mMlluscum contagiosum
lesions on the eyelid may lead to follicular or papillary conjunctivitis . | |
Scabies |
|
Multiple | Erythematous papular lesions | Flexor wrists, finger webs and genitalia | +++ | ||||||||||||||||||
HIV | |||||||||||||||||||||||
Diseases | Etiology | Inherited | Acquired | Demography | History and risk factors | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | BP | Tenderness | Nail pitting | Other | WBC | Platelets | ESR/CRP | Histopathology | Gold standard | Additional findings | |
Immunologic disorders | Dermatitis herpetiformis[6] | Autoimmune disorder as a result of gluten sensitivity leading to the formation of IgA antibodies | – | + | Any, mean age of disease onset is 2nd-4th decade |
|
Multiple |
|
|
– | + | – | – | Nl | – | – |
|
Nl | Nl | Nl |
|
Direct immunofluorescence microscopy (DIF) - presence of granular deposits of IgA within the dermal papillae |
|
Immune deficiency | Wiskott-Aldrich syndrome[7] |
|
+ | – | Seen almost exclusively in males in infancy |
|
Multiple |
|
Rash can involve lesions located at the same areas of classical atopic dermatitis:
extensor surfaces of extremities and cheeks or scalp |
– | + | + | – | Nl | – | – | Infants can present with petechiae, prolonged bleeding from umbilicus or circumcision, purpura, hematemesis, melena, epistaxis, hematuria or unusal bruising |
|
Thrombocytopenia | Nl |
|
Clinical manifestation |
|
Hyper-IgE syndrome[8] |
|
+ | – | Rare, begin in infancy |
|
Multiple |
|
|
+ | + | – | – | Nl | – | – |
|
|
Nl | Nl |
|
Clinical and laboratory findings |
| |
DiGeorge syndrome | |||||||||||||||||||||||
Severe combined immunodeficiency (SCID) | |||||||||||||||||||||||
Ataxia telangiectasia | |||||||||||||||||||||||
Diseases | Etiology | Inherited | Acquired | Demography | History and risk factors | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | BP | Tenderness | Nail pitting | Other | WBC | Platelets | ESR/CRP | Histopathology | Gold standard | Additional findings | |
Metabolic Diseases | Phenylketonuria | ||||||||||||||||||||||
Tyrosinemia | |||||||||||||||||||||||
Histidinemia | |||||||||||||||||||||||
Multiple carboxylase deficiency | |||||||||||||||||||||||
Nutritional deficiencies | Zinc deficiency | ||||||||||||||||||||||
Niacin (B3) deficiency | |||||||||||||||||||||||
Pyridoxine (B6) deficiency | |||||||||||||||||||||||
Biotin (B7) deficiency | |||||||||||||||||||||||
Malignancy | Mycosis fungoides | ||||||||||||||||||||||
Histiocytosis X | |||||||||||||||||||||||
Medications | Infliximab | ||||||||||||||||||||||
Category | Diseases | Etiology | Inherited | Acquired | Demography | History | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | BP | Tenderness | Nail pitting | Other | WBC | Platelets | ESR/CRP | Histopathology | Gold standard | Additional findings |
References
- ↑ Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF (2009). "Allergic and irritant contact dermatitis". Eur J Dermatol. 19 (4): 325–32. doi:10.1684/ejd.2009.0686. PMID 19447733.
- ↑ Bains SN, Nash P, Fonacier L (October 2018). "Irritant Contact Dermatitis". Clin Rev Allergy Immunol. doi:10.1007/s12016-018-8713-0. PMID 30293200.
- ↑ Voicu C, Tebeica T, Zanardelli M, Mangarov H, Lotti T, Wollina U, Lotti J, França K, Batashki A, Tchernev G (July 2017). "Lichen Simplex Chronicus as an Essential Part of the Dermatologic Masquerade". Open Access Maced J Med Sci. 5 (4): 556–557. doi:10.3889/oamjms.2017.133. PMC 5535688. PMID 28785363.
- ↑ Thyssen JP, Godoy-Gijon E, Elias PM (June 2013). "Ichthyosis vulgaris: the filaggrin mutation disease". Br. J. Dermatol. 168 (6): 1155–66. doi:10.1111/bjd.12219. PMID 23301728.
- ↑ Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, Bonafé JL, Wilkinson J, Taïeb A, Barrandon Y, Harper JI, de Prost Y, Hovnanian A (June 2000). "Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome". Nat. Genet. 25 (2): 141–2. doi:10.1038/75977. PMID 10835624.
- ↑ Kárpáti S (2012). "Dermatitis herpetiformis". Clin. Dermatol. 30 (1): 56–9. doi:10.1016/j.clindermatol.2011.03.010. PMID 22137227.
- ↑ Buchbinder D, Nugent DJ, Fillipovich AH (2014). "Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments". Appl Clin Genet. 7: 55–66. doi:10.2147/TACG.S58444. PMC 4012343. PMID 24817816.
- ↑ Mogensen TH (April 2013). "STAT3 and the Hyper-IgE syndrome: Clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties". JAKSTAT. 2 (2): e23435. doi:10.4161/jkst.23435. PMC 3710320. PMID 24058807.